ACC 2025 Highlights: Updates on Icosapent Ethyl and Cardiometabolic Risk
In this short video, Prof Gabriel Steg presents a new analysis from REDUCE-IT, looking at the effect of IPE across different baseline LDL-C and reviews results from two new meta-analyses on impact of IPE on MACE and lipid profiles.
Filmed onsite at ACC 2025, this on-demand series features key insights from Prof Philippe Gabriel Steg and Dr Matthew Budoff to interpret the latest data on icosapent ethyl (IPE), including a new analysis from the REDUCE-IT trial on baseline LDL-C, two new meta-analyses and a retrospective study on plaque progression in patients treated with IPE and a PCSK9 inhibitor.
In these concise summaries, the faculty explore the impact of IPE on residual risk and provide some insight on how its effect on lipid profiles may explain what can be seen at the mechanistic level - i.e. at the level of plaque progression and plaque volume.
For more in-depth overviews, head over to the following link:
Educational Objective
- To provide an update and expert perspectives on recent clinical data from the REDUCE-IT trial, meta-analysis and systematic reviews on novel data with icosapent-ethyl.
Target Audience
- Cardiologists
- Internal Medicine
- Lipidologists
More from this programme
Part 1
Icosapent Ethyl: An Update From REDUCE-IT and New Meta-analyses
In this short video, Prof Gabriel Steg presents a new analysis from REDUCE-IT, looking at the effect of IPE across different baseline LDL-C and reviews results from two new meta-analyses on impact of IPE on MACE and lipid profiles.
Part 2
Impact of Icosapent Ethyl and PCSK9 Inhibition on Plaque Progression in CAD
In this short video, Dr Matthew Budoff presents his results from a CT study looking at the effect of IPE +/- PCSK9 inhibitor compared with statin monotherapy on plaque progression in CAD patients and, reflects on recent results from the EVAPORATE trial, which together, provide further insight into the mechanistic basis of plaque regression mediated by IPE.
Faculty Biographies
Philippe Gabriel Steg
Interventional Cardiologist
Prof Philippe Gabriel Steg works as an Interventional Cardiologist and is Director of the Coronary Care Unit of Hôpital Bichat, in Paris, France.
Prof Steg’s research interests are in the field of coronary artery disease. He is a former member of the Board of the French Society of Cardiology, an honorary member of the Institut Universitaire de France, and received the silver medal of the European Society of Cardiology in 2011.
Prof Steg led the TAO and EUROMAX trials and is chairing or co-chairing several trials or registries, such as ODYSSEY-CV Outcomes, CLARIFY, THEMIS. Prof Steg has authored more than 650 articles in peer-reviewed international journals. He is a member of the editorial boards for Circulation, Circulation: Cardiovascular Interventions, the European Heart Journal, and the European Heart Journal – Cardiovascular Pharmacotherapy. He is deputy editor for the…